An ErbB3 antibody, MM-121, is active in cancers with ligand dependent activation

Por Schoeberl, Birgit, Faber, Anthony C., Li, Danan, Liang, Mei-Chih, Crosby, Katherine, Onsum, Matthew, Burenkova, Olga, Pace, Emily, Walton, Zandra, Nie, Lin, Fulgham, Aaron, Song, Youngchul, Nielsen, Ulrik B., Engelman, Jeffrey A., Wong, Kwok-Kin
Publicado em 2010

Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase

Por Manfredi, Mark G., Ecsedy, Jeffrey A., Meetze, Kristan A., Balani, Suresh K., Burenkova, Olga, Chen, Wei, Galvin, Katherine M., Hoar, Kara M., Huck, Jessica J., LeRoy, Patrick J., Ray, Emily T., Sells, Todd B., Stringer, Bradley, Stroud, Stephen G., Vos, Tricia J., Weatherhead, Gabriel S., Wysong, Deborah R., Zhang, Mengkun, Bolen, Joseph B., Claiborne, Christopher F.
Publicado em 2007

Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121)

Por Schoeberl, Birgit, Kudla, Art, Masson, Kristina, Kalra, Ashish, Curley, Michael, Finn, Gregory, Pace, Emily, Harms, Brian, Kim, Jaeyeon, Kearns, Jeff, Fulgham, Aaron, Burenkova, Olga, Grantcharova, Viara, Yarar, Defne, Paragas, Violette, Fitzgerald, Jonathan, Wainszelbaum, Marisa, West, Kip, Mathews, Sara, Nering, Rachel, Adiwijaya, Bambang, Garcia, Gabriela, Kubasek, Bill, Moyo, Victor, Czibere, Akos, Nielsen, Ulrik B, MacBeath, Gavin
Publicado no NPJ Syst Biol Appl (2017)